Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company focused on targeted protein degradation (TPD), has scheduled its third quarter 2024 financial results announcement for October 31, 2024. The company will host a conference call at 8:30 a.m. ET on the same day. Investors can join via phone at +1 (833) 630-2127 (US) or +1 (412) 317-1846 (International). A live webcast will be available on the company's website under the Investors section, with a replay available after the event.
Kymera Therapeutics (NASDAQ: KYMR), una società biofarmaceutica in fase clinica focalizzata sulla degradazione mirata delle proteine (TPD), ha programmato l'annuncio dei suoi risultati finanziari del terzo trimestre 2024 per il 31 ottobre 2024. L'azienda ospiterà una teleconferenza alle 8:30 (ET) lo stesso giorno. Gli investitori possono partecipare telefonicamente al numero +1 (833) 630-2127 (US) o +1 (412) 317-1846 (Internazionale). Sarà disponibile un webcast dal vivo sul sito web dell'azienda nella sezione Investitori, con una registrazione disponibile dopo l'evento.
Kymera Therapeutics (NASDAQ: KYMR), una compañía biofarmacéutica en etapa clínica centrada en la degradación de proteínas dirigida (TPD), ha programado el anuncio de sus resultados financieros del tercer trimestre de 2024 para el 31 de octubre de 2024. La empresa llevará a cabo una conferencia telefónica a las 8:30 a.m. ET el mismo día. Los inversores pueden unirse por teléfono al +1 (833) 630-2127 (EE. UU.) o al +1 (412) 317-1846 (Internacional). Se ofrecerá una transmisión web en vivo en el sitio web de la compañía en la sección de Inversores, con una repetición disponible después del evento.
Kymera Therapeutics (NASDAQ: KYMR), 표적 단백질 분해(TPD)에 집중하는 임상 단계의 생명공학 회사가 2024년 3분기 재무 결과 발표를 2024년 10월 31일로 예정했습니다. 회사는 같은 날 오전 8시 30분(ET)에 컨퍼런스 콜을 개최합니다. 투자자는 +1 (833) 630-2127 (미국) 또는 +1 (412) 317-1846 (국제)로 전화를 통해 참여할 수 있습니다. 회사 웹사이트의 투자자 섹션에서 실시간 웹캐스트가 제공되며, 이벤트 이후 재생도 가능합니다.
Kymera Therapeutics (NASDAQ: KYMR), une entreprise biopharmaceutique en phase clinique axée sur la dégradation ciblée des protéines (TPD), a prévu l'annonce de ses résultats financiers du troisième trimestre 2024 pour le 31 octobre 2024. L'entreprise organisera une conférence téléphonique à 8h30 (ET) le même jour. Les investisseurs peuvent se joindre par téléphone au +1 (833) 630-2127 (États-Unis) ou au +1 (412) 317-1846 (International). Un webcast en direct sera disponible sur le site Web de l'entreprise dans la section Investisseurs, avec une rediffusion disponible après l'événement.
Kymera Therapeutics (NASDAQ: KYMR), ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf die gezielte Proteinabbau (TPD) konzentriert, hat die Bekanntgabe seiner Finanzergebnisse für das dritte Quartal 2024 für den 31. Oktober 2024 angesetzt. Das Unternehmen wird am selben Tag um 8:30 Uhr ET eine Telefonkonferenz durchführen. Investoren können sich telefonisch unter +1 (833) 630-2127 (USA) oder +1 (412) 317-1846 (International) einwählen. Ein Live-Webcast wird auf der Website des Unternehmens im Bereich Investoren verfügbar sein, mit einer Wiederholung nach der Veranstaltung.
- None.
- None.
WATERTOWN, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), will report third quarter 2024 financial results on October 31, 2024, and will host a conference call at 8:30 a.m. ET.
To access the October 31 conference call via phone, please dial +1 (833) 630-2127 (US) or +1 (412) 317-1846 (International) and ask to join the Kymera Therapeutics call. A live webcast of the Company’s conference call will be available under “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. A replay of the webcast will be archived and available following the event.
About Kymera Therapeutics
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on delivering oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Kymera is also progressing degrader oncology programs that target undrugged or poorly drugged proteins to create new ways to fight cancer. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn.
Investor and Media Contact:
Justine Koenigsberg
Vice President, Investor Relations
investors@kymeratx.com
media@kymeratx.com
857-285-5300
FAQ
When will Kymera Therapeutics (KYMR) release Q3 2024 earnings?
How can I listen to Kymera Therapeutics (KYMR) Q3 2024 earnings call?
Where can I find the replay of Kymera Therapeutics (KYMR) Q3 2024 earnings call?
